Vimarsana
Biggest News Aggregation in the World

Page 2 - Between Dec News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Between Dec. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Between Dec Today - Breaking & Trending Today

Baricitinib is safe and effective for treatment of refractory juvenile idiopathic arthritis - Vimarsana News

Baricitinib is safe and effective for treatment of refractory juvenile idiopathic arthritis

1. Time to disease flare was significantly shorter in the placebo group versus baricitinib. 2. There was no difference in serious adverse events between the baricitinib and placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Juvenile idiopathic arthritis (JIA) is defined by the onset of polyarticular joint pain before age 16 and can severely

#VisualAbstract: Sparsentan superior to irbesartan for reduction of proteinuria in patients with IgA nephropathy - Vimarsana News

#VisualAbstract: Sparsentan superior to irbesartan for reduction of proteinuria in patients with IgA nephropathy

Patients in sparsentan group reported a 50% reduction in proteinuria compared to 15% in the irbesartan group at week 36. Complete remission of proteinuria was significantly higher in the sparsentan group. Evidence Rating Level: 1 (Excellent) Study Rundown: IgA nephropathy is the most common cause of primary glomerulonephritis worldwide. Although renin-angiotensin blockers (ARBs), such as irbesartan,

#VisualAbstract: Ritlecitinib superior to placebo in the treatment of alopecia areata among teens and adults - Vimarsana News

#VisualAbstract: Ritlecitinib superior to placebo in the treatment of alopecia areata among teens and adults

1. Patients in the ritlecitinib group showed significant improvements in alopecia symptoms, with Severity of Alopecia Tool (SALT) scores ≤ 20, compared to placebo. 2. Adverse events between groups were comparable; there were no reported deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Alopecia areata is an autoimmune form of hair loss that affects both children

Sparsentan superior to irbesartan for reduction of proteinuria in patients with IgA nephropathy - Vimarsana News

Sparsentan superior to irbesartan for reduction of proteinuria in patients with IgA nephropathy

1. Patients in sparsentan group reported a 50% reduction in proteinuria compared to 15% in the irbesartan group at week 36. 2. Complete remission of proteinuria was significantly higher in the sparsentan group. Evidence Rating Level: 1 (Excellent) Study Rundown: IgA nephropathy is the most common cause of primary glomerulonephritis worldwide. Although renin-angiotensin blockers (ARBs),

Ritlecitinib superior to placebo in the treatment of alopecia areata among teens and adults - Vimarsana News

Ritlecitinib superior to placebo in the treatment of alopecia areata among teens and adults

1. Patients in the ritlecitinib group showed significant improvements in alopecia symptoms, with Severity of Alopecia Tool (SALT) scores ≤ 20, compared to placebo. 2. Adverse events between groups were comparable; there were no reported deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Alopecia areata is an autoimmune form of hair loss that affects both